1. Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018;4(6):e180039.
2. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67-74.
3. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010;28(7):1106-11.
4. Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MF, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110(1):104-9.
5. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056-63.
6. Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464-73.
7. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990-6.
8. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475-87.
9. Delobel JB, Gnep K, Ospina JD, Beckendorf V, Chira C, Zhu J, et al. Nomogram to predict rectal toxicity following prostate cancer radiotherapy. PLoS One. 2017;12(6):e0179845.
10. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62(5):1297-308.
11. Kupelian PA, Reddy CA, Carlson TP, Willoughby TR. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume? Cancer J. 2002;8(1):62-6.
12. Marzi S, Arcangeli G, Saracino B, Petrongari MG, Bruzzaniti V, Iaccarino G, et al. Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68(1):41-9.
13. Ishikawa H, Tsuji H, Kamada T, Hirasawa N, Yanagi T, Mizoe JE, et al. Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66(4):1084-91.
14. Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter R. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol. 2001;59(1):65-70.
15. Afkhami Ardekani M, Ghaffari H, Navaser M, Zoljalali Moghaddam SH, Refahi S. Effectiveness of rectal displacement devices in managing prostate motion: a systematic review. Strahlenther Onkol. 2021;197(2):97-115.
16. van Lin EN, Hoffmann AL, van Kollenburg P, Leer JW, Visser AG. Rectal wall sparing effect of three different endorectal balloons in 3D conformal and IMRT prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(2):565-76.
17. Wong AT, Schreiber D, Agarwal M, Polubarov A, Schwartz D. Impact of the use of an endorectal balloon on rectal dosimetry during stereotactic body radiation therapy for localized prostate cancer. Pract Radiat Oncol. 2016;6(4):262-7.
18. Teh BS, Lewis GD, Mai W, Pino R, Ishiyama H, Butler EB. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer. Cancer Commun (Lond). 2018;38(1):11.
19. Wortel RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, Incrocci L. Moderate hypofractionation in intermediate and high risk, localized prostate cancer: Health-related quality of life from the randomized, phase 3 HYPRO trial. Int J Radiat Oncol Biol Phys. 2018.
20. Deville C, Both S, Bui V, Hwang WT, Tan KS, Schaer M, et al. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon. Radiat Oncol. 2012;7:76.
21. Vlachaki MT, Teslow TN, Ahmad S. Impact of endorectal balloon in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with IMRT. Med Dosim. 2007;32(4):281-6.
22. Smeenk RJ, van Lin EN, van Kollenburg P, Kunze-Busch M, Kaanders JH. Anal wall sparing effect of an endorectal balloon in 3D conformal and intensity-modulated prostate radiotherapy. Radiother Oncol. 2009;93(1):131-6.
23. Patel RR, Orton N, Tome WA, Chappell R, Ritter MA. Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer. Radiother Oncol. 2003;67(3):285-94.
24. Vargas C, Mahajan C, Fryer A, Indelicato D, Henderson RH, McKenzie C, et al. Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69(4):1110-6.
25. Wootton LS, Kudchadker RJ, Beddar AS, Lee AK. Effectiveness of a novel gas-release endorectal balloon in the removal of rectal gas for prostate proton radiation therapy. J Appl Clin Med Phys. 2012;13(5):3945.
26. Hedrick SG, Fagundes M, Robison B, Blakey M, Renegar J, Artz M, et al. A comparison between hydrogel spacer and endorectal balloon: An analysis of intrafraction prostate motion during proton therapy. J Appl Clin Med Phys. 2017;18(2):106-12.
27. Agren Cronqvist AK, Kallman P, Turesson I, Brahme A. Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours. Acta Oncol. 1995;34(6):851-60.
28. Vanneste BGL, van Wijk Y, Lutgens LC, Van Limbergen EJ, van Lin EN, van de Beek K, et al. Dynamics of rectal balloon implant shrinkage in prostate VMAT : Influence on anorectal dose and late rectal complication risk. Strahlenther Onkol. 2018;194(1):31-40.
29. Qamhiyeh S, Geismar D, Pottgen C, Stuschke M, Farr J. The effects of motion on the dose distribution of proton radiotherapy for prostate cancer. J Appl Clin Med Phys. 2012;13(3):3639.
30. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol. 2004;73(1):21-32.
31. Dale E, Hellebust TP, Skjonsberg A, Hogberg T, Olsen DR. Modeling normal tissue complication probability from repetitive computed tomography scans during fractionated high-dose-rate brachytherapy and external beam radiotherapy of the uterine cervix. Int J Radiat Oncol Biol Phys. 2000;47(4):963-71.
32. Elsayed H, Bolling T, Moustakis C, Muller SB, Schuller P, Ernst I, et al. Organ movements and dose exposures in teletherapy of prostate cancer using a rectal balloon. Strahlenther Onkol. 2007;183(11):617-24.
33. Hille A, Schmidberger H, Tows N, Weiss E, Vorwerk H, Hess CF. The impact of varying volumes in rectal balloons on rectal dose sparing in conformal radiation therapy of prostate cancer. A prospective three-dimensional analysis. Strahlenther Onkol. 2005;181(11):709-16.
34. Wachter S, Gerstner N, Dorner D, Goldner G, Colotto A, Wambersie A, et al. The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52(1):91-100.
35. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48(3):635-42.
36. Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;54(5):1314-21.
37. Zapatero A, Garcia-Vicente F, Modolell I, Alcantara P, Floriano A, Cruz-Conde A, et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J Radiat Oncol Biol Phys. 2004;59(5):1343-51.
38. Tucker SL, Dong L, Cheung R, Johnson J, Mohan R, Huang EH, et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(5):1589-601.
39. Jackson A, Skwarchuk MW, Zelefsky MJ, Cowen DM, Venkatraman ES, Levegrun S, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys. 2001;49(3):685-98.